Sociedad Americana de Hirudoterapia

Treatment of heparin-induced thrombocytopenia

Review published in Ann Pharmacother (2002)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosEnsayos clínicosDager WE et al. · Ann Pharmacother, 2002

Abstract

OBJECTIVE: To describe heparin-induced thrombocytopenia (HIT or HIT-2), an immune-mediated adverse reaction to heparin or low-molecular-weight heparin. Available treatment options and considerations in developing a therapy approach are discussed. DATA SOURCES: A search of the National Library of Medicine (1992-June 2001) was done to identify pertinent literature. Additional references were reviewed from selected articles. STUDY SELECTION: Articles related to laboratory recognition and treatment options of HIT, including the use of agents in selected clinical conditions, were reviewed and included. CONCLUSIONS: HIT is a rare but potentially severe adverse reaction to heparin that was, until recently, poorly understood and had limited treatment options. Recent advances describing the recognition and clinical manifestations of immune-mediated HIT, including recently available antithrombotic treatment options, have dramatically changed outcomes for patients having this syndrome.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsAnticoagulantsArginineChondroitin SulfatesClinical Trials as TopicCoronary DiseaseDermatan SulfateDrug CombinationsFemaleHeparinHeparan SulfateHirudin Therapy

Resumen

Review of HIT-2 treatment options including direct thrombin inhibitors such as lepirudin and argatroban; describes laboratory recognition and clinical manifestations of immune-mediated HIT.

Por qué esto importa para la hirudoterapia

This article describes heparin-induced thrombocytopenia (HIT or HIT-2) as an immune-mediated adverse reaction to heparin or low-molecular-weight heparin and discusses available antithrombotic treatment options based on a literature search through June 2001. The abstract notes that recent advances in recognition and treatment options have improved outcomes for these patients. The abstract does not name any specific antithrombotic agent and makes no mention of hirudin, leeches, or hirudotherapy. There is no defensible connection to ASH's domain based on this abstract alone; any hirudin-related link would require external knowledge not present in the text.

Citación

Treatment of heparin-induced thrombocytopenia.

Dager WE et al. · Ann Pharmacother, 2002

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.